Skip to content

Insider · CIK 0002000284

Kurtoglu Metin

officer

Files at RNAC (Cartesian Therapeutics, Inc.). First filing Nov 18, 2024, latest Dec 11, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $2.4M sold

Signals

This insider’s open-market buys and sells, scored.

ScoreSideCompanyValueSharesHoldings changePrice contextFiled
20WeaksellRNAC
Cartesian Therapeutics, Inc.
$345k13,664-22%-
55Moderatesell 3RNAC
Cartesian Therapeutics, Inc.
$649k38,689-76%-
60Notablesell 3RNAC
Cartesian Therapeutics, Inc.
$1.4M82,368-107%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 9, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+10,763$1.41$15k61,796Dec 11, 2024
Dec 9, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-6,224$25.26$157k55,572Dec 11, 2024
Dec 9, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-4,539$25.83$117k51,033Dec 11, 2024
Dec 10, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+2,901$1.41$4,09053,934Dec 11, 2024
Dec 10, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-2,901$24.35$71k51,033Dec 11, 2024
Dec 9, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-10,763--82,000Dec 11, 2024
Dec 10, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-2,901--79,099Dec 11, 2024
Nov 19, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+200$1.41$28251,233Nov 21, 2024
Nov 19, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-200$19.50$3,90051,033Nov 21, 2024
Nov 20, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+5,700$1.41$8,03756,733Nov 21, 2024
Nov 20, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-5,600$17.28$97k51,133Nov 21, 2024
Nov 20, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-100$18.09$1,80951,033Nov 21, 2024
Nov 21, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+32,789$1.41$46k83,822Nov 21, 2024
Nov 21, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-32,789$16.67$547k51,033Nov 21, 2024
Nov 19, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-200--131,252Nov 21, 2024
Nov 20, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-5,700--125,552Nov 21, 2024
Nov 21, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-32,789--92,763Nov 21, 2024
Nov 14, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+25,900$1.41$37k76,933Nov 18, 2024
Nov 14, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-21,900$16.33$358k55,033Nov 18, 2024
Nov 14, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-4,000$17.06$68k51,033Nov 18, 2024
Nov 15, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+22,068$1.41$31k73,101Nov 18, 2024
Nov 15, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-22,068$17.20$379k51,033Nov 18, 2024
Nov 18, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Common Stock
+34,400$1.41$49k85,433Nov 18, 2024
Nov 18, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-16,672$18.19$303k68,761Nov 18, 2024
Nov 18, 2024RNAC
Cartesian Therapeutics, Inc.
SOpen-market sale
Common Stock
-17,728$18.58$329k51,033Nov 18, 2024
Nov 14, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-25,900--187,920Nov 18, 2024
Nov 15, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-22,068--165,852Nov 18, 2024
Nov 18, 2024RNAC
Cartesian Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative
-34,400--131,452Nov 18, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.